ReviewJournal of clinical and experimental hepatology
Epidemiology and Disease Burden of Alcohol Associated Liver Disease.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 100 citations in OpenAlex.
- Association Between Metabolic Obesity Phenotypes and Alcohol-Associated Fatty Liver Disease Among US Adults: A NHANES 2013-2018 Analysis.Journal of clinical medicine · 2026Article
- Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study.Hepatology (Baltimore, Md.) · 2026Observational
- Provider attitudes, practices, and barriers in alcohol-associated liver disease care: Findings from the CASL ALD SIG national survey.Canadian liver journal · 2026Article
- Spontaneous Recovery and Mortality in Patients With ALD Referred for Early Liver Transplantation.The American journal of gastroenterology · 2026Article
- Immunomodulatory effects of mesenchymal stem cell-derived extracellular vesicles on NLRP3 inflammasome activation in the adult mouse brain after chronic ethanol exposure.Molecular biology reports · 2026Article
- Article
- Application of artificial intelligence in hepatology.Frontiers in digital health · 2026Review
- Recompensation in Patients With Alcohol-Related Liver Disease-A Multicenter Study.Gastro hep advances · 2026Article
- Limited but Growing Use of Medications for Alcohol Use Disorder by Gastroenterologists: A Medicare Analysis, 2016-2024.Gastro hep advances · 2026Review
- Liver Macrophage Changes during Early Adaptation to Alcohol Exposure.The American journal of pathology · 2026Article
- Screening for medicine and food homologous ingredients targeting ALDH2 to alleviate acute ethanol-induced liver injury.Frontiers in nutrition · 2026Article
- Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?Current hepatology reports · 2025Article
- Article
- The Pathophysiology of Alcohol-Associated Liver Disease: Focusing on Superoxide Dismutase 1 as a Therapeutic Target.Biology · 2025Review
- Integrated approaches to reduce alcohol use in people with liver disease: a scoping review and quantitative analysis.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Article
- An AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease.Digestive diseases and sciences · 2025Article
- Effects of soluble epoxide hydrolase inhibition on liver injury and gut microbiota in mice chronically fed ethanol.Alcohol, clinical & experimental research · 2025Article
- Article
- Ethanol-Induced Depression: Exploring the Underlying Molecular Mechanisms.Cellular and molecular neurobiology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consumption of alcohol in excess leads to substantial medical, economic, and societal burdens. Approximately 5.3% of all global deaths may be attributed to alcohol consumption. Moreover, the burden of alcohol associated liver disease (ALD) accounts for 5.1% of all disease and injury worldwide. Alcohol use disorder (AUD) affects men more than women globally with significant years of life loss to disability in low, middle and well-developed countries. Precise data on global estimates of alcohol related steatosis, alcohol related hepatitis, and alcohol related cirrhosis have been challenging to obtain. In the United States (US), alcohol related steatosis has been estimated at 4.3% based on NHANES data which has remained stable over 14 years. However, alcohol-related fibrotic liver disease has increased over the same period. In those with AUD, the prevalence of alcohol related hepatitis has been estimated at 10-35%. Globally, the prevalence of alcohol-associated cirrhosis has been estimated at 23.6 million individuals for compensated cirrhosis and 2.46 million for those with decompensated cirrhosis. The contribution of ALD to global mortality and disease burden of liver related deaths is substantial. In 2016 liver disease related to AUD contributed to 50% of the estimated liver disease deaths for age groups 15 years and above. Data from the US report high cost burdens associated with those admitted with alcohol-related liver complications. Finally, the recent COVID-19 pandemic has been associated with marked increase in alcohol consumption worldwide and will likely increase the burden of ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.